Disrupted iron homeostasis causes dopaminergic neurodegeneration in mice

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 13, 2016, Pages 3428-3435

  Matak, Pavle ^a   Matak, Andrija ^a   Moustafa, Sarah ^a   Aryal, Dipendra K ^a   Benner, Eric J ^a   Wetsel, William ^a   Andrews, Nancy C ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Dopaminergic neuron; Ferroportin; Iron; Neurodegeneration; Transferrin receptor

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; CD71 ANTIGEN; DOPAMINE; FERROPORTIN; HOMOVANILLIC ACID; IRON; CATION TRANSPORT PROTEIN; METAL TRANSPORTING PROTEIN 1; TFRC PROTEIN, MOUSE; TRANSFERRIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; FEMALE; GENE EXPRESSION; GLYCOLYSIS; HOMEOSTASIS; IN VIVO STUDY; IRON HOMEOSTASIS; IRON TRANSPORT; MALE; MOUSE; NERVE CELL NECROSIS; NERVE DEGENERATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEPLETION; SUBSTANTIA NIGRA; UNFOLDED PROTEIN RESPONSE; 129 MOUSE; ANIMAL; BRAIN; C57BL MOUSE; DEFICIENCY; GENETICS; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY;

ANIMALS; BRAIN; CATION TRANSPORT PROTEINS; DOPAMINERGIC NEURONS; FEMALE; HOMEOSTASIS; IRON; MALE; MICE; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, KNOCKOUT; NERVE DEGENERATION; RECEPTORS, TRANSFERRIN;

EID: 84962077743     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1519473113     Document Type: Article

References (85)

1. Crichton RR, Dexter DT, Ward RJ (2011) Brain iron metabolism and its perturbation in neurological diseases. J Neural Transm (Vienna) 118(3):301-314.
2. Snyder AM, Connor JR (2009) Iron, the substantia nigra and related neurological disorders. Biochim Biophys Acta 1790(7):606-614.
3. Levy JE, Jin O, Fujiwara Y, Kuo F, Andrews NC (1999) Transferrin receptor is necessary for development of erythrocytes and the nervous system. Nat Genet 21(4): 396-399.
4. Ned RM, Swat W, Andrews NC (2003) Transferrin receptor 1 is differentially required in lymphocyte development. Blood 102(10):3711-3718.
5. Chen AC, Donovan A, Ned-Sykes R, Andrews NC (2015) Noncanonical role of transferrin receptor 1 is essential for intestinal homeostasis. Proc Natl Acad Sci USA 112(37): 11714-11719.
6. Barrientos T, et al. (2015) Metabolic catastrophe in mice lacking transferrin receptor in muscle. EBioMedicine 2(11):1705-1717.
7. Xu W, et al. (2015) Lethal cardiomyopathy in mice lacking transferrin receptor in the heart. Cell Reports 13(3):533-545.
8. Hentze MW, Muckenthaler MU, Andrews NC (2004) Balancing acts: Molecular control of mammalian iron metabolism. Cell 117(3):285-297.
9. Rouault TA (2013) Iron metabolism in the CNS: Implications for neurodegenerative diseases. Nat Rev Neurosci 14(8):551-564.
10. Fretham SJ, et al. (2012) Temporal manipulation of transferrin-receptor-1-dependent iron uptake identifies a sensitive period in mouse hippocampal neurodevelopment. Hippocampus 22(8):1691-1702.
11. Hill JM, Ruff MR, Weber RJ, Pert CB (1985) Transferrin receptors in rat brain: Neuropeptide- like pattern and relationship to iron distribution. Proc Natl Acad Sci USA 82(13):4553-4557.
12. Hentze MW, Muckenthaler MU, Galy B, Camaschella C (2010) Two to tango: Regulation of mammalian iron metabolism. Cell 142(1):24-38.
13. Schneider SA, Bhatia KP (2012) Syndromes of neurodegeneration with brain iron accumulation. Semin Pediatr Neurol 19(2):57-66.
14. Dexter DT, et al. (1989) Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem 52(6):1830-1836.
15. Gorell JM, et al. (1995) Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease. Neurology 45(6):1138-1143.
16. Riederer P, et al. (1989) Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 52(2):515-520.
17. Morris CM, Edwardson JA (1994) Iron histochemistry of the substantia nigra in Parkinson's disease. Neurodegeneration 3(4):277-282.
18. Oakley AE, et al. (2007) Individual dopaminergic neurons show raised iron levels in Parkinson disease. Neurology 68(21):1820-1825.
19. Lei P, et al. (2012) Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. Nat Med 18(2):291-295.
20. Savica R, et al. (2009) Anemia or low hemoglobin levels preceding Parkinson disease: A case-control study. Neurology 73(17):1381-1387.
21. Logroscino G, Chen H, Wing A, Ascherio A (2006) Blood donations, iron stores, and risk of Parkinson's disease. Mov Disord 21(6):835-838.
22. Mariani S, et al. (2016) Association between sex, systemic iron variation and probability of Parkinson's disease. Int J Neurosci 126(4):354-360.
23. Buchanan DD, Silburn PA, Chalk JB, Le Couteur DG, Mellick GD (2002) The Cys282Tyr polymorphism in the HFE gene in Australian Parkinson's disease patients. Neurosci Lett 327(2):91-94.
24. Pichler I, et al.; PD GWAS Consortium; International Parkinson's Disease Genomics Consortium; Wellcome Trust Case Control Consortium 2; Genetics of Iron Status Consortium (2013) Serum iron levels and the risk of Parkinson disease: A Mendelian randomization study. PLoS Med 10(6):e1001462.
25. Xia J, Xu H, Jiang H, Xie J (2015) The association between the C282Y and H63D polymorphisms of HFE gene and the risk of Parkinson's disease: A meta-analysis. Neurosci Lett 595:99-103.
26. Bäckman CM, et al. (2006) Characterization of a mouse strain expressing Cre recombinase from the 3' untranslated region of the dopamine transporter locus. Genesis 44(8):383-390.
27. Donovan A, et al. (2005) The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis. Cell Metab 1(3):191-200.
28. Sanz E, et al. (2009) Cell-type-specific isolation of ribosome-associated mRNA from complex tissues. Proc Natl Acad Sci USA 106(33):13939-13944.
29. Sotnikova TD, et al. (2005) Dopamine-independent locomotor actions of amphetamines in a novel acute mouse model of Parkinson disease. PLoS Biol 3(8):e271.
30. Rensvold JW, et al. (2013) Complementary RNA and protein profiling identifies iron as a key regulator of mitochondrial biogenesis. Cell Reports 3(1):237-245.
31. XuW, Barrientos T, Andrews NC (2013) Iron and copper in mitochondrial diseases. Cell Metab 17(3):319-328.
32. Sterky FH, Lee S, Wibom R, Olson L, Larsson NG (2011) Impaired mitochondrial transport and Parkin-independent degeneration of respiratory chain-deficient dopamine neurons in vivo. Proc Natl Acad Sci USA 108(31):12937-12942.
33. Mootha VK, et al. (2003) PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34(3): 267-273.
34. Subramanian A, et al. (2005) Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102(43):15545-15550.
35. Laplante M, Sabatini DM (2012) mTOR signaling in growth control and disease. Cell 149(2):274-293.
36. Chung CY, et al. (2005) Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection. Hum Mol Genet 14(13):1709-1725.
37. Yasuda M, Tanaka Y, Ryu M, Tsuda S, Nakazawa T (2014) RNA sequence reveals mouse retinal transcriptome changes early after axonal injury. PLoS One 9(3):e93258.
38. Kanaan NM, et al. (2015) The longitudinal transcriptomic response of the substantia nigra to intrastriatal 6-hydroxydopamine reveals significant upregulation of regeneration- associated genes. PLoS One 10(5):e0127768.
39. Herrero-Mendez A, et al. (2009) The bioenergetic and antioxidant status of neurons is controlled by continuous degradation of a key glycolytic enzyme by APC/C-Cdh1. Nat Cell Biol 11(6):747-752.
40. Rodriguez-Rodriguez P, Fernandez E, Almeida A, Bolaños JP (2012) Excitotoxic stimulus stabilizes PFKFB3 causing pentose-phosphate pathway to glycolysis switch and neurodegeneration. Cell Death Differ 19(10):1582-1589.
41. Hetz C, Mollereau B (2014) Disturbance of endoplasmic reticulum proteostasis in neurodegenerative diseases. Nat Rev Neurosci 15(4):233-249.
42. Hauser DN, Hastings TG (2013) Mitochondrial dysfunction and oxidative stress in Parkinson's disease and monogenic parkinsonism. Neurobiol Dis 51:35-42.
43. Silva RM, et al. (2005) CHOP/GADD153 is a mediator of apoptotic death in substantia nigra dopamine neurons in an in vivo neurotoxin model of parkinsonism. J Neurochem 95(4):974-986.
44. Pietrangelo A, Caleffi A, Corradini E (2011) Non-HFE hepatic iron overload. Semin Liver Dis 31(3):302-318.
45. Miyajima H (2015) Aceruloplasminemia. Neuropathology 35(1):83-90.
46. Jeong SY, David S (2006) Age-related changes in iron homeostasis and cell death in the cerebellum of ceruloplasmin-deficient mice. J Neurosci 26(38):9810-9819.
47. Jeong SY, et al. (2011) Iron insufficiency compromises motor neurons and their mitochondrial function in Irp2-null mice. PLoS One 6(10):e25404.
48. Zhou QY, Palmiter RD (1995) Dopamine-deficient mice are severely hypoactive, adipsic, and aphagic. Cell 83(7):1197-1209.
49. Pacelli C, et al. (2015) Elevated mitochondrial bioenergetics and axonal arborization size are key contributors to the vulnerability of dopamine neurons. Curr Biol 25(18): 2349-2360.
50. Youle RJ, van der Bliek AM (2012) Mitochondrial fission, fusion, and stress. Science 337(6098):1062-1065.
51. Batlevi Y, La Spada AR (2011) Mitochondrial autophagy in neural function, neurodegenerative disease, neuron cell death, and aging. Neurobiol Dis 43(1):46-51.
52. Friedman LG, et al. (2012) Disrupted autophagy leads to dopaminergic axon and dendrite degeneration and promotes presynaptic accumulation of α-synuclein and LRRK2 in the brain. J Neurosci 32(22):7585-7593.
53. Ekstrand MI, et al. (2007) Progressive parkinsonism in mice with respiratory-chaindeficient dopamine neurons. Proc Natl Acad Sci USA 104(4):1325-1330.
54. Bolaños JP, Almeida A, Moncada S (2010) Glycolysis: A bioenergetic or a survival pathway? Trends Biochem Sci 35(3):145-149.
55. Young JE, et al. (2009) Polyglutamine-expanded androgen receptor truncation fragments activate a Bax-dependent apoptotic cascade mediated by DP5/Hrk. J Neurosci 29(7):1987-1997.
56. Fernandes KA, Harder JM, Kim J, Libby RT (2013) JUN regulates early transcriptional responses to axonal injury in retinal ganglion cells. Exp Eye Res 112:106-117.
57. Perier C, et al. (2007) Two molecular pathways initiate mitochondria-dependent dopaminergic neurodegeneration in experimental Parkinson's disease. Proc Natl Acad Sci USA 104(19):8161-8166.
58. Chuang CL, Lu YN, Wang HC, Chang HY (2014) Genetic dissection reveals that Akt is the critical kinase downstream of LRRK2 to phosphorylate and inhibit FOXO1, and promotes neuron survival. Hum Mol Genet 23(21):5649-5658.
59. Yamada M, Kida K, Amutuhaire W, Ichinose F, Kaneki M (2010) Gene disruption of caspase-3 prevents MPTP-induced Parkinson's disease in mice. Biochem Biophys Res Commun 402(2):312-318.
60. Malagelada C, Jin ZH, Greene LA (2008) RTP801 is induced in Parkinson's disease and mediates neuron death by inhibiting Akt phosphorylation/activation. J Neurosci 28(53):14363-14371.
61. Zumbrennen-Bullough KB, et al. (2014) Abnormal brain iron metabolism in Irp2 deficient mice is associated with mild neurological and behavioral impairments. PLoS One 9(6):e98072.
62. Galy B, et al. (2005) Altered body iron distribution and microcytosis in mice deficient in iron regulatory protein 2 (IRP2). Blood 106(7):2580-2589.
63. Senyilmaz D, et al. (2015) Regulation of mitochondrial morphology and function by stearoylation of TFR1. Nature 525(7567):124-128.
64. Schmidt PJ, Toran PT, Giannetti AM, Bjorkman PJ, Andrews NC (2008) The transferrin receptor modulates Hfe-dependent regulation of hepcidin expression. Cell Metab 7(3):205-214.
65. Shoffner JM, Watts RL, Juncos JL, Torroni A, Wallace DC (1991) Mitochondrial oxidative phosphorylation defects in Parkinson's disease. Ann Neurol 30(3):332-339.
66. Liu Y, Koyutürk M, Maxwell S, Zhao Z, Chance MR (2012) Integrative analysis of common neurodegenerative diseases using gene association, interaction networks and mRNA expression data. AMIA Jt Summits Transl Sci Proc 2012:62-71.
67. Rakshit H, Rathi N, Roy D (2014) Construction and analysis of the protein-protein interaction networks based on gene expression profiles of Parkinson's disease. PLoS One 9(8):e103047.
68. Racette BA (2014) Manganism in the 21st century: The Hanninen lecture. Neurotoxicology 45:201-207.
69. Aisen P, Aasa R, Redfield AG (1969) The chromium, manganese, and cobalt complexes of transferrin. J Biol Chem 244(17):4628-4633.
70. Suárez N, Eriksson H (1993) Receptor-mediated endocytosis of a manganese complex of transferrin into neuroblastoma (SHSY5Y) cells in culture. J Neurochem 61(1): 127-131.
71. Crooks DR, Ghosh MC, Braun-Sommargren M, Rouault TA, Smith DR (2007) Manganese targets m-aconitase and activates iron regulatory protein 2 in AF5 GABAergic cells. J Neurosci Res 85(8):1797-1809.
72. Ben Gedalya T, et al. (2009) Alpha-synuclein and polyunsaturated fatty acids promote clathrin-mediated endocytosis and synaptic vesicle recycling. Traffic 10(2):218-234.
73. Chai YJ, et al. (2013) The secreted oligomeric form of α-synuclein affects multiple steps of membrane trafficking. FEBS Lett 587(5):452-459.
74. Fujibayashi A, et al. (2008) Human RME-8 is involved in membrane trafficking through early endosomes. Cell Struct Funct 33(1):35-50.
75. Chen C, et al. (2013) Snx3 regulates recycling of the transferrin receptor and iron assimilation. Cell Metab 17(3):343-352.
76. Bucci C, et al. (1995) Co-operative regulation of endocytosis by three Rab5 isoforms. FEBS Lett 366(1):65-71.
77. Trischler M, Stoorvogel W, Ullrich O (1999) Biochemical analysis of distinct Rab5- and Rab11-positive endosomes along the transferrin pathway. J Cell Sci 112(Pt 24): 4773-4783.
78. Lumsden AL, Henshall TL, Dayan S, Lardelli MT, Richards RI (2007) Huntingtindeficient zebrafish exhibit defects in iron utilization and development. Hum Mol Genet 16(16):1905-1920.
79. Singh A, Qing L, Kong Q, Singh N (2012) Change in the characteristics of ferritin induces iron imbalance in prion disease affected brains. Neurobiol Dis 45(3):930-938.
80. Franklin BJ, Paxinos G (2007) The Mouse Brain in Stereotaxic Coordinates (Elsevier, San Diego), 3rd Ed.
81. Benner EJ, et al. (2004) Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. Proc Natl Acad Sci USA 101(25):9435-9440.
82. Sesack SR, Hawrylak VA, Matus C, Guido MA, Levey AI (1998) Dopamine axon varicosities in the prelimbic division of the rat prefrontal cortex exhibit sparse immunoreactivity for the dopamine transporter. J Neurosci 18(7):2697-2708.
83. Gaier ED, et al. (2013) Peptidylglycine α-amidating monooxygenase heterozygosity alters brain copper handling with region specificity. J Neurochem 127(5):605-619.
84. Jones SR, et al. (1998) Profound neuronal plasticity in response to inactivation of the dopamine transporter. Proc Natl Acad Sci USA 95(7):4029-4034.
85. Veznedaroglu E, Milner TA (1992) Elimination of artifactual labeling of hippocampal mossy fibers seen following pre-embedding immunogold-silver technique by pretreatment with zinc chelator. Microsc Res Tech 23(1):100-101.